Amgen VP gets RSUs, options; 50 shares withheld

Amgen executive Matthew C. Busch, VP Finance & CAO, reported routine equity compensation grants and related tax withholding.

Rhea-AI Filing Summary

Amgen executive Matthew C. Busch, VP Finance & CAO, reported routine equity compensation grants and related tax withholding. He received 455 shares of common stock as Restricted Stock Units, including 45 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These RSUs vest in four equal 25% installments starting on 5/5/2027 and are settled in common shares.

Busch also received 2,969 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from 5/5/2027 until expiration on 5/5/2036. To cover tax obligations, 50 shares of common stock were disposed of at $329.59 per share as a tax-withholding transaction, not an open-market sale. After these transactions, he directly holds 4,385 common shares.

Insights

Equity compensation analyst

Routine Amgen executive equity grants with small tax withholding.

The filing shows Matthew C. Busch, Amgen’s VP Finance & CAO, receiving standard long-term incentives: 455 RSU-based shares (including Dividend Equivalents) and 2,969 non-qualified stock options, all vesting in four annual installments beginning on 5/5/2027.

The 50-share disposition at $329.59 per share is a tax-withholding event rather than an open-market sale, so it carries little informational signal about sentiment. Following these transactions, Busch directly holds 4,385 shares, indicating the activity is modest relative to his overall equity position.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Busch Matthew C.

Role VP, Finance & CAO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	50	$329.59	$16K
Grant/Award	Nqso (Right to Buy)	2,969	$329.59	$979K
Grant/Award	Common Stock	455	$0.00	$0.00

Holdings After Transaction: Nqso (Right to Buy) — 2,969 contracts (Direct); Common Stock — 4,385 shares (Direct)

Footnotes (3)

1. F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. F2. These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. F3. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

Key Figures

RSU shares granted: 455 shares Dividend Equivalents included: 45 shares Options granted: 2,969 options +4 more

7 metrics

RSU shares granted 455 shares Restricted Stock Units granted, including 45 Dividend Equivalents, vesting from May 5, 2027

Dividend Equivalents included 45 shares Dividend Equivalents credited to unvested RSUs under Equity Incentive Plan

Options granted 2,969 options Non-qualified stock options to buy Amgen common stock

Option exercise price $329.59 per share Conversion or exercise price of non-qualified stock options

Option expiration date May 5, 2036 Expiration date of non-qualified stock options if unexercised

Tax-withheld shares 50 shares Shares disposed of to satisfy tax liability at $329.59 per share

Shares after transactions 4,385 shares Direct Amgen common stock holdings following reported Form 4 transactions

Key Terms

Restricted Stock Units (RSUs), Dividend Equivalents (DEs), non-qualified stock options, Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Dividend Equivalents (DEs) financial

"These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan"

non-qualified stock options financial

"These non-qualified stock options were granted pursuant to the Equity Incentive Plan"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Equity Incentive Plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan)"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

tax-withholding disposition financial

"Payment of exercise price or tax liability by delivering securities"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) executive Matthew C. Busch receive in this Form 4 filing?

Matthew C. Busch received 455 shares of Amgen common stock as Restricted Stock Units and 2,969 non-qualified stock options. Both awards were granted under Amgen’s Equity Incentive Plan and are structured to vest gradually over four years starting on May 5, 2027.

How do the new Amgen (AMGN) RSUs for Matthew C. Busch vest?

The 455 Restricted Stock Units for Matthew C. Busch vest in four equal 25% installments beginning May 5, 2027. Upon vesting, each RSU converts into one share of Amgen common stock, providing a staggered equity delivery schedule that aligns with multi-year retention incentives.

What are the terms of Matthew C. Busch’s new Amgen (AMGN) stock options?

Busch was granted 2,969 non-qualified stock options with a $329.59 exercise price. These options vest and become exercisable in four equal annual 25% installments starting May 5, 2027, and remain exercisable until their expiration on May 5, 2036, if vested.

Why did Matthew C. Busch dispose of 50 Amgen (AMGN) shares in this filing?

The 50 Amgen shares were disposed of solely to satisfy tax obligations, not as an open-market sale. The transaction used a tax-withholding mechanism at $329.59 per share, where shares are delivered back to the company to cover exercise price or tax liabilities associated with equity awards.

How many Amgen (AMGN) shares does Matthew C. Busch hold after these transactions?

After the reported transactions, Matthew C. Busch directly holds 4,385 shares of Amgen common stock. This figure reflects his position following the RSU grant, stock option grant, and the 50-share tax-withholding disposition executed to cover associated tax obligations on his equity compensation.

What are Dividend Equivalents (DEs) mentioned in the Amgen (AMGN) Form 4?

Dividend Equivalents are credits tied to unvested RSUs that mirror dividends on Amgen shares. Busch’s 455 RSUs include 45 DEs, which are added to his RSUs and paid out in Amgen common stock on a one-to-one basis following the same vesting schedule, plus cash for any fractional share amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 09:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busch Matthew C.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		A		455(1)	A	$0	4,435	D
Common Stock	05/06/2026		F		50	D	$329.59	4,385(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	$329.59	05/05/2026		A		2,969		05/05/2027(3)	05/05/2036	Common Stock	2,969	$329.59	2,969	D

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

2. These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

3. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

	/s/ Matthew C. Busch	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)